CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
靶向 PD-1/PD-L1 轴用于癌症治疗：纳米技术综述
英文原题：Targeting the PD-1/PD-L1 axis for cancer treatment: a review on nanotechnology.
查看英文原题
Targeting the PD-1/PD-L1 axis for cancer treatment: a review on nanotechnology.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
自Doxil问世以来，纳米药物进入肿瘤学领域已近三十年，但获批的纳米药物产品仍然很少。纳米技术能否成为减少住院床位占用的切实工具？目前已有多种获批的抗PD-1／PD-L1抗体或基于CAR-T 细胞的疗法，但免疫治疗领域远未成熟。免疫疗法会成为癌症治疗的第四大支柱吗？本综述总结了目前利用靶向PD-1／PD-L1的纳米载体开展免疫治疗的研究进展。材料科学、治疗药物及制剂设计方面的知识，有望推动获得高效治疗结果。
展开英文摘要原文
Although nanomedicines have been in the oncology field for almost three decades with the introduction of doxil, only a few nanomedicine products have reached approval. Can nanotechnology be a realistic tool to reduce the number of hospital beds? At present, several clinically approved anti-PD-1/PD-L1 antibodies or CAR T cell-based therapies are available; however, the immunotherapy field is far from mature.
Will immunotherapy be the fourth pillar of cancer treatment? In this review, we summarized the current status of immunotherapy using PD-1/PD-L1-targeting nanocarriers. The knowledge on material science, therapeutic agents and formulation designs could pave the way for high-efficacy treatment outcomes.
论文信息
- 作者
- Tran TH、Phuong Tran TT
- 第一作者单位
- Faculty of Pharmacy, PHENIKAA University, Hanoi 12116, Vietnam.
- 通讯作者单位
- Department of Life Sciences, University of Science and Technology of Hanoi Vietnam Academy of Science and Technology, Hanoi, Vietnam.
- 文献类型
- 综述
- 期刊
- Royal Society open science2022 Apr
- 原文标识
- PubMed 35425626 · DOI 10.1098/rsos.211991
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →